These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 17272676)

  • 21. [Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation by mycophenolate mofetil in a murine model].
    Huang H; Zheng W; Lin M; Fu J; Zhang R
    Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):191-3. PubMed ID: 12133455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained suppression of peripheral blood immune functions by treatment with mycophenolate mofetil correlates with reduced severity of cardiac allograft rejection.
    Klupp J; van Gelder T; Dambrin C; Regieli JJ; Boeke K; Billingham ME; Morris RE
    J Heart Lung Transplant; 2004 Mar; 23(3):334-51. PubMed ID: 15019644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consideration of mycophenolate mofetil for idiopathic pulmonary fibrosis.
    Altschuler EL
    Med Hypotheses; 2001 Dec; 57(6):701-2. PubMed ID: 11918429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy.
    Engl T; Makarević J; Relja B; Natsheh I; Müller I; Beecken WD; Jonas D; Blaheta RA
    BMC Cancer; 2005 Jan; 5():4. PubMed ID: 15644133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group.
    Transplantation; 1999 Aug; 68(3):391-6. PubMed ID: 10459543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Use of mycophenolate mofetil in kidney transplantation].
    Hrvacevic R; Ignjatovic Lj; Vavic N
    Vojnosanit Pregl; 2001; 58(4):415-9. PubMed ID: 11712223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats.
    Romero F; Rodríguez-Iturbe B; Parra G; González L; Herrera-Acosta J; Tapia E
    Kidney Int; 1999 Mar; 55(3):945-55. PubMed ID: 10027931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effects of TGF-beta 1 and TGF-beta 2 on extracellular matrix production, proliferation, migration, and collagen contraction of human Tenon's capsule fibroblasts in pseudoexfoliation and primary open-angle glaucoma.
    Kottler UB; Jünemann AG; Aigner T; Zenkel M; Rummelt C; Schlötzer-Schrehardt U
    Exp Eye Res; 2005 Jan; 80(1):121-34. PubMed ID: 15652533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The influence of mycophenolate mofetil upon the maturation and allostimulatory activity of cultured dendritic cell progenitors and the effects of tolerance induction in allograft recipients].
    Han CH; Li HF; Wang YX; Zhang M; Wang Y; Yin M; Min ZL; Zheng KL
    Zhonghua Yi Xue Za Zhi; 2005 May; 85(19):1327-32. PubMed ID: 16029632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiological and metabolic actions of mycophenolate mofetil on cultured newborn rat cardiomyocytes in normoxia and in simulated ischemia.
    Bès S; Tatou E; Vandroux D; Tissier C; Rochette L; Athias P
    Fundam Clin Pharmacol; 2004 Jun; 18(3):287-98. PubMed ID: 15147280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction.
    Mias C; Lairez O; Trouche E; Roncalli J; Calise D; Seguelas MH; Ordener C; Piercecchi-Marti MD; Auge N; Salvayre AN; Bourin P; Parini A; Cussac D
    Stem Cells; 2009 Nov; 27(11):2734-43. PubMed ID: 19591227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro.
    Stracke S; Ramudo L; Keller F; Henne-Bruns D; Mayer JM
    Transplant Proc; 2006 Apr; 38(3):766-70. PubMed ID: 16647466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice.
    Yu CC; Yang CW; Wu MS; Ko YC; Huang CT; Hong JJ; Huang CC
    J Lab Clin Med; 2001 Jul; 138(1):69-77. PubMed ID: 11433230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maintenance immunosuppression with mycophenolate mofetil and corticosteroids in pediatric kidney transplantation: temporary benefit but not without risk.
    Cransberg K; Cornelissen M; Lilien M; Van Hoeck K; Davin JC; Nauta J
    Transplantation; 2007 Apr; 83(8):1041-7. PubMed ID: 17452893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
    Nash RA; Johnston L; Parker P; McCune JS; Storer B; Slattery JT; Furlong T; Anasetti C; Appelbaum FR; Lloid ME; Deeg HJ; Kiem HP; Martin PJ; Schubert MM; Witherspoon RP; Forman SJ; Blume KG; Storb R
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):495-505. PubMed ID: 15983549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.
    Krämer S; Loof T; Martini S; Rückert M; Wang Y; Böhler T; Shimizu F; Kawachi H; Neumayer HH; Peters H
    Am J Physiol Renal Physiol; 2005 Aug; 289(2):F359-68. PubMed ID: 15769934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
    Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
    Maris MB; Sandmaier BM; Storer BE; Maloney DG; Shizuru JA; Agura E; Kliem C; Pulsipher M; Maziarz RT; McSweeney PA; Wade J; Langston AA; Chauncey TR; Bruno B; Blume KG; Storb R
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):454-65. PubMed ID: 16545729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ex vivo lymphocyte proliferative function is severely inhibited in renal transplant patients on mycophenolate mofetil treatment.
    Hutchinson P; Jose M; Atkins RC; Holdsworth SR
    Transpl Immunol; 2004; 13(1):55-61. PubMed ID: 15203129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.